Physician profile
Randy D Watson
NPI 1295737005
$990.93
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2024: $24.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $24.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $203.59 | 2019 | |
| Janssen Biotech, INC. | $173.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.33 | 2019 | |
| Braintree Laboratories, INC. | $99.06 | 2019 | |
| Boston Scientific Corporation | $68.98 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.03 | 2019 | |
| Shionogi INC | $54.66 | 2019 | |
| Ironwood Pharmaceuticals, INC | $43.73 | 2019 | |
| Pfizer INC. | $32.10 | 2019 | |
| Ferring Pharmaceuticals INC. | $29.83 | 2019 | |
| Daiichi Sankyo INC. | $27.68 | 2019 | |
| Gilead Sciences, INC. | $15.53 | 2019 | |
| Allergan, INC. | $15.05 | 2019 | |
| Intercept Pharmaceuticals, INC. | $12.46 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.